Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1266218.RAfkL9uKcFADjB18B0nNasoZuUOw2mAf5NOrBoP9ovs5E130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1266218.RAfkL9uKcFADjB18B0nNasoZuUOw2mAf5NOrBoP9ovs5E130_assertion type Assertion NP1266218.RAfkL9uKcFADjB18B0nNasoZuUOw2mAf5NOrBoP9ovs5E130_head.
- NP1266218.RAfkL9uKcFADjB18B0nNasoZuUOw2mAf5NOrBoP9ovs5E130_assertion description "[KRAS mutation is present in 30%-50% of colorectal cancers and is associated with the inefficacy of anti-epidermal growth factor receptor therapy, while the impact of KRAS on survival is seldom discussed.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1266218.RAfkL9uKcFADjB18B0nNasoZuUOw2mAf5NOrBoP9ovs5E130_provenance.
- NP1266218.RAfkL9uKcFADjB18B0nNasoZuUOw2mAf5NOrBoP9ovs5E130_assertion evidence source_evidence_literature NP1266218.RAfkL9uKcFADjB18B0nNasoZuUOw2mAf5NOrBoP9ovs5E130_provenance.
- NP1266218.RAfkL9uKcFADjB18B0nNasoZuUOw2mAf5NOrBoP9ovs5E130_assertion SIO_000772 25713893 NP1266218.RAfkL9uKcFADjB18B0nNasoZuUOw2mAf5NOrBoP9ovs5E130_provenance.
- NP1266218.RAfkL9uKcFADjB18B0nNasoZuUOw2mAf5NOrBoP9ovs5E130_assertion wasDerivedFrom befree-2016 NP1266218.RAfkL9uKcFADjB18B0nNasoZuUOw2mAf5NOrBoP9ovs5E130_provenance.
- NP1266218.RAfkL9uKcFADjB18B0nNasoZuUOw2mAf5NOrBoP9ovs5E130_assertion wasGeneratedBy ECO_0000203 NP1266218.RAfkL9uKcFADjB18B0nNasoZuUOw2mAf5NOrBoP9ovs5E130_provenance.